SCHEMBL17128913

SCHEMBL17128913

CCOC(=O)n1nc(-c2ccncn2)cc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.42
▸ KLK3 P07288 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ CLK1 P49759 1/20 0.36
▸ UBE2N P61088 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ JMJD6 Q6NYC1 2/20 0.36
▸ CSNK1D P48730 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ NAMPT P43490 1/20 0.34
▸ CFTR P13569 1/20 0.34
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13815667 0.87 KLK3 (0.45) F2KLK3MAPK1CYP2D6GSK3B
SCHEMBL17128907 0.83 ALDH1A1 (0.49) KLK3ALDH1A1MAPK1TSHRNPC1
SCHEMBL17128964 0.77 PDE10A (0.34) ALDH1A1MAPK1TSHRNPC1LMNA
SCHEMBL13815635 0.75 F2 (0.43) F2ALDH1A1MAPK1TSHRPOLB
SCHEMBL14688239 0.74 ALDH1A1 (0.67) ALDH1A1MAPK1TSHRNPC1LMNA
SCHEMBL13815632 0.73 F2 (0.38) F2ALDH1A1MAPK1HPGDCLK1
SCHEMBL15813913 0.73 HSP90AA1 (0.41) F2MAPK1CSNK1DCYP2D6GSK3B
SCHEMBL24696357 0.69 MAPT (0.45) ALDH1A1MAPK1TSHRNPC1LMNA
SCHEMBL13896445 0.68 F2 (0.46) F2ALDH1A1LMNAGSK3B
SCHEMBL31555626 0.67 PDE4D (0.35) ALDH1A1MAPK1TSHRNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342795-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-07-09 — — US disclosed
EP-3126366-B1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-06-06 — — EP disclosed
US-20170173014-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 — — US disclosed
US-20170173014-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 — — US disclosed
WO-2015144801-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342795-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors ROS1, NOX1, NOX4 F2 2236/4885KLK3 3937/4885ALDH1A1 23/4885
US-20170173014-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS ROS1, NOX1, NOX4 F2 2707/4885KLK3 3871/4885ALDH1A1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback